FDA decision on October 30 looms for Inovio Pharmaceuticals stock

Published on 10/17/2026 at 20:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The 52-week high was USD 2.72 as of October 16, 2026. Inovio Pharmaceuticals stock last traded at USD 0.99 on October 16, 2026, down 4.80 percent on Nasdaq.

FDA date and market position

The FDA has set October 30, 2026 as the target decision date for INO-3107.
Inovio stock stood 63.60 percent below its 52-week high as of October 16, 2026.
Inovio Pharmaceuticals stock last traded at USD 0.99 on October 16, 2026 at 4:00 p.m. ET, down 4.80 percent versus the Nasdaq prior close.
Inovio had a market capitalization of USD 68.4 million and a trailing P/E of minus 0.85.

INO, US45773H4092, Illustration mit AI erstellt.

The FDA has set October 30, 2026 as the target action date for INO-3107, Inovio Pharmaceuticals' investigational treatment for recurrent respiratory papillomatosis. The company last traded at USD 0.99 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.80 percent from the USD 1.04 prior close.

FDA decision set for October 30

Inovio's official program overview says the FDA accepted the Biologics License Application for review in December 2025 and set the Prescription Drug User Fee Act target date for October 30, 2026. The company is seeking approval for INO-3107 in recurrent respiratory papillomatosis, a rare disease involving recurring growths in the respiratory tract, according to INOVIO.

Second-quarter loss falls to USD 6.01 million

In the second quarter of 2026, Inovio reported a net loss of USD 6.01 million, or USD 0.07 per diluted share. The result compared with a USD 23.5 million loss, or USD 0.61 per share, in the second quarter of 2025. The earlier loss included a USD 13.9 million non-cash gain tied to fair-value changes in warrant liabilities, as described in the Yahoo Finance transcript.

Stock sits below its yearly high

At USD 0.99, the stock was 63.60 percent below its 52-week high of USD 2.72 and 76.79 percent above its 52-week low of USD 0.56 on October 16, 2026. Trading volume was 2,050,682 shares, below the average volume of 4,082,432 shares. The Nasdaq listing and the USD 0.56 to USD 2.72 range were also identified by MarketBeat on October 14, 2026.

Valuation and cash runway

Inovio's market capitalization was USD 68.4 million on October 16, 2026, while its trailing P/E was minus 0.85. During its second-quarter call, management said the company expected operational net cash burn of USD 18 million in the third quarter of 2026 and projected cash resources into late first quarter of 2027, subject to its assumptions and potential financing.

Comparison with peers

INO (Nasdaq, USD): minus 4.80 percent, P/E minus 0.85, market capitalization USD 68.4 million

Moderna (Nasdaq, USD): minus 7.82 percent, P/E minus 27.32, market capitalization USD 87.0 billion

BioNTech (Nasdaq, USD): minus 2.76 percent, P/E minus 11.57, market capitalization USD 22.0 billion

Next date for investors

The October 30, 2026 FDA decision is the next major date tied to Inovio's lead program. The company has described the review as being in its final stages, while the FDA's decision remains the decisive near-term event for the program.